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TRAIL (tumour necrosis factor-related apoptosis inducing ligand) is most often reported to induce apop-
tosis in tumour cells. It is expressed in artery walls but its role and regulation in vascular pathologies is
little studied.
We aimed tomeasure the effect of genetic deletion of TRAIL on atherosclerosis in amousemodel. TRAIL
wasmainlyexpressed inendothelium, smoothmuscle cells andmacrophageswithinplaques. Theabsence
of TRAIL in chow and in fat-fed mice led to greater lesion coverage in aortae (8 weeks, % area± SEM),polipoprotein E-deﬁcient mice
therosclerosis
RAIL
poptosis
n=7–8, 1.24±0.2 (no TRAIL, chow diet) vs. 0.42±0.1, p<0.01 and 3.4±0.8 (no TRAIL, Western diet)
vs. 0.94±0.2, p<0.01 and larger, smooth muscle cell rich lesions at aortic roots than control mice (8
weeks, mean lesion area/total cross sectional area± SEM, n=7–8, 0.17±0.01 (no TRAIL, chow diet) vs.
0.135±0.006, p<0.05 and 0.36±0.03 (no TRAIL, Western diet) vs. 0.23±0.02, p<0.05) particularly at
early time points. The larger early lesions appeared to be as a result of increased smooth muscle cells in
, pro-
rosis.lesions of TRAIL deﬁcient
early stages of atheroscle
. Introduction
The pathogenesis of atherosclerosis is a complex process
nvolving inﬂammation, cell proliferation, apoptosis and necro-
is. The tumour necrosis factor (TNF) superfamily of cytokines
ncludes tumour necrosis factor-related apoptosis-inducing ligand
TRAIL/TNFSF10); the primary ligand involved in apoptosis sig-
alling in this family. TRAIL is a 40kDa type II transmembrane
rotein that induces apoptosis by interaction with two ‘death’
eceptors (TRAIL R1 and R2) [1]. In addition, there are 3 ‘decoy’
eceptors for TRAIL: TRAILR3, R4and the soluble receptorosteopro-
egerin, which, when bound to the ligand, do not induce apoptosis
2,3]. TRAIL exists in soluble and membrane bound forms and its
xpressionhasbeendetected in avarietyof human tissues [4]. Lym-
hocytes, monocytes and neutrophils have been shown to express
RAIL, and soluble TRAIL (sTRAIL) is detectable in humans in both
ealth and disease [5,6].
Following TRAIL ligand–receptor binding, downstream sig-
alling leads to apoptosis by the caspase-dependent and
itochondrial pathways [7]. However, TRAIL signalling can also
romote cell survival and proliferation via induction of transcrip-
∗ Corresponding author. Tel.: +44 114 2261432; fax: +44 114 2268898.
E-mail address: s.francis@shefﬁeld.ac.uk (S. Francis).
1 Current address: Norwich Medical School, University of East Anglia, Norwich,
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Open access under CC BY-NC-ND license.atherosclerotic animals. We conclude that TRAIL attenuates plaque size at
© 2011 Elsevier Ireland Ltd. 
tion factors NF-кB and c-jun, the mitogen-activated protein kinase
ERK1 and the phosphatidylinositol 3-kinase P13K/serine/threonine
kinase Akt pathway signalling which is of central importance to
angiogenesis and endothelial cell survival [8,9]. Whilst TRAIL can
induce apoptosis of many malignant and transformed cell lines,
there are conﬂicting data surrounding the effects of TRAIL on nor-
mal human cells, including vascular smooth muscle cells (VSMCs)
and endothelial cells. Published data have shown that TRAIL can
induce apoptosis of human VSMC and endothelial cells [10,11] yet,
under conditions of trophic factor withdrawal, TRAIL promotes
their survival and proliferation [8,12,13]. These conﬂicting data
have led to uncertainty regarding the role of TRAIL in vascular
biology and disease.
TRAIL ligand is detectable in stable and unstable human
atherosclerotic plaques and levels of sTRAIL are lower in patients
with coronary disease compared to disease-free controls [14,15].
These ﬁndings have led to the suggestion that TRAIL may have a
protective role in the atherosclerotic process.
Recent data indicate that TRAIL promotes VSMC prolifera-
tion and neointimal formation after arterial injury induced using
a femoral cuff in mice [16]. Using the ApoE−/− mouse model
of atherogenesis, Secchiero et al. showed that administration of
Open access under CC BY-NC-ND license.recombinant humanTRAIL to diabetic ApoE−/− mice led to a greater
VSMC lesion content and a reduced overall lesion size [17]. These
ﬁndings indicating that TRAIL is pro-proliferative contrast with
those of Sato et al.who demonstrated induction of VSMC apoptosis
by TRAIL-expressing T cells isolated from patients with ACS [11].
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iven these conﬂicting data, we sought to further clarify the role
f TRAIL in atherogenesis by genetic deletion of TRAIL in ApoE−/−
ice, feeding of a Western diet and assessment of atherosclerosis.
. Methods
.1. Animals
TRAIL−/− mice, on a C57BL/6 background, were the kind gift of
ark Smyth, Peter MacCallum Cancer Institute, Australia under
mgen materials transfer agreement 200308096. ApoE−/− mice,
lso on a C57BL/6 background, were bred in house. All mice were
sed in accordance with UK legislation (1986 Animals (Scientiﬁc
rocedures) Act) and were housed in a controlled environment
ith a 12h light/dark cycle at 22 ◦C. All animal experiments were
pproved by the University of Shefﬁeld Project Review Committee
nd carried out under a UK Home Ofﬁce Project Licence. Following
e-derivation, TRAIL−/− mice were crossed with ApoE−/− mice to
reate a double knockout mouse colony. Genotype was conﬁrmed
y polymerase chain reaction. All animals were fed standard chow
ntil they reached 6 weeks of age (20g). Male TRAIL−/−/ApoE−/−
ice and TRAIL+/+/ApoE−/− controls were then fed chow or a
holate-free ‘Western’ diet (n=6–8 for each group, Special Diet Ser-
ices, Essex, UK). Allmicewere observed daily andweighedweekly
o monitor their health. After 8 or 12 weeks of high fat diet, the
nimals were euthanized by pharmacological overdose of pento-
arbitone. Blood was collected by cardiac puncture and the mice
ere perfusion-ﬁxed with 10% (w/v) buffered formalin. The aor-
ic sinus from each animal was dissected, embedded in parafﬁn
nd serially sectioned (5m). The thoracic aorta was removed and
ig. 1. TRAIL expression in an atheromatous aortic sinus lesion (8 weeks). (A) TRAIL prote
o show individual cell associated expression. (C) Macrophage staining (F480 antigen) in
RAIL positive and one TRAIL negative macrophage). (D) Negative control (isotype).s 215 (2011) 348–354 349
ﬁxed in 4% (w/v) buffered formalin prior to en facepreparation. Aor-
tic sinus sections were stained with Alcian Blue/Elastic Van Gieson
for atheromatous lesions. The thoracic aortaewere stainedwith Oil
Red O and pinned onto wax.
2.2. Immunohistochemistry
Immunohistochemistry was carried out on aortic sinus sec-
tions. Sections were dewaxed and incubated with VSMC -smooth
muscle actin primary antibody (Dako SMA Clone 1A4, diluted
1:150) for 1h, then with a secondary biotinylated goat anti-mouse
antibody (Vector Labs), followed by ABC solution (Vector Labs).
Immunogenicity was visualized with DAB (Sigma) and sections
were counterstained with Carazzi’s haematoxylin. Macrophages
were detected using F480 and the Mac3 antibody (M3/84 mono-
clonal antibody 550292 BD Pharmingen). Sections were dewaxed
and antigen retrieval was carried out using citrate buffer. Dako
serum-free protein block was applied to the sections for 1h, fol-
lowed by incubation with the primary antibody (1:50 dilution) for
2h. A secondary antibody (biotinylated anti-rat IgG, Vector Labs)
was applied for 1h, the slideswere incubated inABC-alkaline phos-
phatase (Vector labs) and the Vector Blue stain applied. For TRAIL
staining an iso HC DAB kit (Biogenex) was used. Apoptotic cells
were detected using Apoptag® Fluorescein in situ reagents (Milli-
pore).2.3. Morphometry
Total lesion area or area of positive staining was determined
for each section/aorta, respectively, using computer assisted image
in in medial and peri-adventitial cells (arrows denote VSMC). (B) High power of (A)
the same lesion as (A) and (B) to show macrophage expression (arrows denote one
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nalysis (NIS-elements/Lucia G software, Nikon UK). Data were
enerated for mean lesion area and lesion area:cross-sectional
rea (CSA) ratio of the aortic sinus. For the en face aortic prepa-
ations, area of positive staining for Oil Red O is expressed
s a percentage of total aortic area. For immunohistochemical
uantitation, positive staining Mac3 is expressed as an area pro-
ortional to total lesion area. Cells staining positive for TRAIL,
SMA and apoptosis (TUNEL) were counted as a proportion
f the total cells in 0.1mm2 plaque to create a percentage
ndex. A minimum of 5 areas of plaque were counted per sec-
ion.
ig. 2. The effect of TRAIL on atheroma development in ApoE−/− mice fed chow or a
estern diet. Analysis of atheromatous lesions in en face aortae preparations using
il red O staining from TRAIL−/−ApoE−/− and ApoE−/− mice fed chow or Western
iet for 8 weeks (A) or 12 weeks (B) showed that the absence of TRAIL leads to an
ncrease in % lesion area (expressed as a percentage of total surface area of the aorta).
or (A), *p<0.01 vs. ApoE−/− fed chow and Western, respectively, at 8 weeks, n=8,
ann–Whitney U Test. For (B), signiﬁcance only seen on a chow diet after 12 weeks
f feeding, *p<0.001 vs. ApoE−/− chow, n=9–14, Mann–Whitney U Test.s 215 (2011) 348–354
2.4. Plasma analysis
Plasma alanine aminotransferase, aspartate aminotransferase,
total cholesterol, low density and high density lipoproteins and
random glucose were measured by the biochemistry department
at the Northern General Hospital, Shefﬁeld.
2.5. Statistical analysisData were analysed by non-parametric testing with the
Mann–Whitney U and Kruskal Wallis tests using GraphPad Prism
4 software. Data are shown as median and interquartile range or
Fig. 3. The effect of TRAIL on lesional area at the aortic sinus. ApoE−/− or
TRAIL−/−ApoE−/− mice were fed chow or Western diet for 8 weeks (A) or 12 weeks,
n=9–14 (B) and lesion area assessed by Alcian Blue/Elastic Van Gieson staining.
ApoE−/− mice on both diets had smaller lesions than TRAIL−/−ApoE−/− mice but only
at the 8 week timepoint. *p<0.05, Mann–Whitney U test.
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ean± SEM unless otherwise stated. Signiﬁcance is denoted by
<0.05.
. Results
.1. Phenotype and biochemical analysis
Mice were generated from the breeding programme in the
xpected Mendelian ratio. TRAIL−/−ApoE−/− mice fed on chow for
oth 8 weeks and 12 weeks weighed more than ApoE−/− controls
n chow at the same timepoint (32.81±0.534 vs. 30.31±0.377g
poE−/− chow, all n=8 at 8 weeks, p<0.01; 33.58±0.375 vs.
9.43±0.702g ApoE−/− chow, all n=8 at 12 weeks, p<0.01).
Plasma cholesterol increased as expected with dietary fat con-
ent (Supplementary Tables 1 and 2). There was no signiﬁcant
ifference in plasma cholesterol between the two mouse strains
tudied.Mice fed theWestern diet had lowermean randomglucose
evels compared to the mice fed chow. There was no signiﬁcant
ifference in plasma glucose or liver enzymes between the two
ransgenic strains.
.2. Expression of TRAIL in murine atherosclerotic plaquesTRAIL was expressed throughout the plaque but predominantly
n the smoothmuscle cell layer (Fig. 1A and B). A fewmacrophages
n the lesions appeared toexpress TRAIL (Fig. 1C). TRAIL is a secreted
olecule and some positive staining was seen in the extracellular
atrix. There was no difference in the % of cells staining positively
ig. 4. Representative images of atheromatous lesions in ApoE−/− and TRAIL−/−ApoE−/−
B) fed chow for 12 weeks. Note larger lesions at all sites for the TRAIL−/−ApoE−/− mice com
C) and TRAIL−/−ApoE−/− mice (D) fed Western diet for 8 weeks. Note larger lesions for ths 215 (2011) 348–354 351
for TRAIL in lesions after 8weeks compared to 12weeks on aWest-
ern Diet (data not shown). There were no TRAIL positive cells in
ApoE−/−TRAIL−/− mice.
3.3. The effect of TRAIL on atheromatous lesion size in the aorta
and aortic sinus
Analysis of lesion area in en face aortae demonstrated that
TRAIL−/−ApoE−/− mice fed chow or Western diet for 8 weeks had
signiﬁcantly greater mean lesion area in the aorta compared to
ApoE−/− controls (Fig. 2). In the 12-week feeding regime, a differ-
ence was only apparent when mice were fed a regular chow diet
(Fig. 2B). Analysis of aortic sinus lesion area and lesion:CSA also
showed that TRAIL−/−ApoE−/− mice fed choworWestern diets for 8
weeks had a larger lesion area at this site compared toApoE−/− con-
trols (Fig. 3A). No differences between the groups in lesion area at
the aortic sinus were observed at 12 weeks. Representative images
of the en face preparation and aortic sinus are shown in Fig. 4.
3.4. The effect of TRAIL on plaque composition
There were more smooth muscle cells in aortic sinus lesions
from TRAIL−/−ApoE−/− animals fed both chow and Western diet
compared with controls at the early time point of 8 weeks. Signiﬁ-
cance between the groups (ApoE−/− vs. TRAIL−/−ApoE−/−) was only
reached formally at the 8-week time point where mice were fed
regular chow (Fig. 5A). Although there was a slight increase, there
was no actual signiﬁcant difference in the VSMC index between
mice. En face aorta preparations from ApoE−/− mice (A) and TRAIL−/−ApoE−/− mice
pared to ApoE−/− mice. Scale bar represents 2mm. Aortic sinus lesions in ApoE−/−
e TRAIL−/−ApoE−/− mice compared to ApoE−/− mice. Scale bar represents 200m.
352 V. Watt et al. / Atherosclerosis 215 (2011) 348–354
Fig. 5. The effect of TRAIL on atheroma lesion VSMC composition in ApoE−/−
mice fed a high fat diet. VSMC indices in aortic sinus lesions from ApoE−/− and
TRAIL−/−ApoE−/− mice fed theWestern or Paigen diet for 8 weeks. These data show
that deletion of TRAIL in ApoE−/− mice fed the Western diet for 8 weeks leads to
greater positive staining for -smooth muscle actin in the lesion (A) compared to
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Fig. 6. The effect of TRAIL on macrophages in atheromatous lesions. Quantitation
of Mac 3 immunohistochemistry of aortic sinus from ApoE−/− and TRAIL−/−ApoE−/−
mice fed choworWesternor diet for 8 (A) or 12 (B)weeks.Macrophage staining after
8 weeks on a chow diet was too low to quantify accurately. There was no signiﬁcant
difference inMac 3 staining betweenmouse genotypes or with diet. Area of positiveicewith functional TRAIL. The data in (B) are from lesions harvested after 12weeks
f feeding. Positive staining in the lesion is expressed as a ratio to total lesion area,
ata are presented asmean± SEM, analysis by theMann–WhitneyU test, signiﬁcant
esults denoted by *p<0.05.
RAIL−/−ApoE−/− and ApoE−/− mice fed chow or Western diet at
he 12-week timepoint (Fig. 5B). There was also a suggestion that
he increase in smooth muscle cells in the atherosclerotic plaques
romTRAIL−/−ApoE−/− animals at 12weeks coincidedwith a reduc-
ion in apoptosis as analysed by TUNEL but, again, this did not reach
tatistical signiﬁcance (Supplementary ﬁgure).
For macrophage staining, immunohistochemistry was not per-
ormed on sections frommice fed chow for 8weeks, asmacrophage
ontent of the lesions were too small for analysis. Mice fed aWest-
rn diet for 8 or 12 weeks or fed chow for 12 weeks did not
eveal anystatistically signiﬁcantdifference inmacrophagecontent
Fig. 6A and B).
. Discussion
This is the ﬁrst report of an atherosclerosis study in double deﬁ-
ient TRAIL and apolipoprotein E mice. In fat fed ApoE−/− mice,
RAIL was expressed predominantly in smooth muscle cells, but
lso in some endothelial cells and macrophages in aortic sinus
esions. These data onmajor expression in vascular smoothmuscle
ells concur with previous studies on human atherosclerosis and
ouse aorta from 10 month old ApoE−/− mice [14].
We show here that TRAIL causes an attenuation of atheroscle-
otic lesion formation in ApoE−/− mice fed a fat-enriched diet. The
ttenuating effect of TRAIL in the ApoE−/− model of atherosclerosisstaining for Mac 3 is expressed as a ratio to total lesion area, data are presented as
mean± SEM, analysis by the Mann–Whitney U test, signiﬁcant results denoted by
*p<0.05.
was only seen in mice fed regular chow or a Western diet for the
shortest period of time (8 weeks). These data suggest there may be
a temporal component to the attenuating effect of TRAIL on lesion
formation. Nevertheless, we cannot exclude the possibility that the
effects of TRAIL early in disease formation may not only be lost as
the disease develops, but also that, at later stages of lesion develop-
ment, the effects of TRAIL on lesion progression may change as the
developing plaque changes from a lesion characterised by cell pro-
liferation and migration into a more cytopenic lesion with cellular
necrosis and apoptosis.
We observed a clear difference in VSMC lesion content in pro-
atherosclerotic mice lacking TRAIL where aortic lesions contained
more VSMC than in ApoE−/− mice after 8 weeks of Western diet.
This effect was only clearly seen at this timepoint and although
there was a positive trend for an increase in VSMC lesion content
at 12weeks, this was not signiﬁcant in either chow orWestern diet
fed animals. Interestingly, and in support, data on apoptosis at the
12 weeks timepoint also indicated a trend towards a reduction in
VSMC apoptosis inWestern diet fed TRAIL deﬁcient atherosclerotic
animals.
It is notable that our data do not replicate the ﬁndings of Sec-
chiero et al. where TRAIL appeared to cause an increase in VSMC
lesion content [17]. This may be explained by the different disease
models used; Secchiero’s mice were rendered diabetic and given
recombinant human TRAIL, whereas our mice were not diabetic
and had either native TRAIL or no TRAIL.
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Secchiero et al. propose that the apparent beneﬁcial effect of
RAIL in atheroma developmentmay bemediated, in part, through
romotion of VSMC migration and proliferation, leading to an
ncrease in VSMC content of the ﬁbrous cap, conferring greater
laque stability. However, this does not sit well with in vitro evi-
ence showing that T-cell expression of TRAIL is a potent inducer of
SMC apoptosis [11]. In addition, VSMC proliferation in atheroma
evelopment would potentially lead to larger lesions, yet Sec-
hiero’swork and the data presented here indicate that TRAIL leads
o a reduction in lesion size.
More recentdata fromKavurmaandBennetthavedemonstrated
hat soluble TRAIL can induce VSMC proliferation in vitro at phys-
ological concentrations (1ng/ml) and this effect is mediated via
ctivation of NF-B and induction of insulin-like growth factor-1
eceptor [13]. However, the authors also found that at higher con-
entrations (400ng/ml), sTRAIL induced VSMC apoptosis. Whilst
hese levels are far in excess of physiological levels of sTRAIL, TRAIL
s also present in the circulation in membrane-bound form. Cross-
inkage of the ligand has a more potent cell-killing effect and more
losely resembles themembrane-bound formof the ligand found in
ivo [18]. It is arguablewhether treatment of VSMCswith very high
evels of sTRAIL is comparable to treatment with cross-linked or
embrane-bound ligand, which is known to induce VSMC apopto-
is. Therefore, it is possible that the different experimental models
sed and the known difference in potency between membrane-
ound TRAIL and soluble forms of the ligand may explain these
pparently conﬂictingdata. It isnotknownwhether sTRAILorTRAIL
xpressed on the surface of T cells has a more dominant effect on
ell population control in human physiology.
Recent data from Chan et al. [16] indicate that TRAIL promotes
roliferation in a cuff-induced vascular injury. Although thismodel
as some features of atherosclerosis; namely an inﬂammatorybasis
nd VSMC proliferation, it lacks an atherogenic stimulus which,
uite plausibly, might promote apoptotic activity due to TRAIL
ather than proliferation.
Since TRAIL is thought to mediate some of its functions through
egulation of the immune response and induction of apoptosis of
nﬂammatory cells, it is surprising that our data showed no effect
f TRAIL on the macrophage content of the atheromatous plaques.
lthough a trend was seen for greater macrophage staining in the
poE−/− mice fedWestern diet at 12weeks these data did not reach
igniﬁcance. Whilst these data do not provide conclusive evidence
hat deletion of TRAIL affects the macrophage content of athero-
atous lesions, this does not exclude TRAIL-induced apoptosis of
nﬁltrating macrophages as a potential mechanism for the reduc-
ion in lesion size observed. Evidence from in vitro studies has
hown that TRAIL does induce apoptosis of both human andmurine
acrophages [19], andSecchiero’s studydemonstrated that admin-
stration of rhTRAIL to diabetic ApoE−/− mice led to a reduction in
he number of plaque-inﬁltrating macrophages and an increase in
acrophage apoptosis [17]. It is known that inﬁltration of mono-
ytes and macrophages occurs early in the developing lesion and
t is possible that the reduction in lesion size seen here at earlier
ime-points may be mediated, in part, by control of macrophage
umbers by TRAIL.
The observation that deletion of a potentially inﬂammatory
ytokine or mechanism results in enhancement of atherosclero-
is is not one in isolation. Though deletion of many inﬂammatory
ytokines and chemokines, when crossed onto an atherosclerotic
ackground in the mouse, produce reduction in plaque volume,
eletion of the TNF signalling receptor anddeletionofmacrophage-
peciﬁc NF-B pathways have been associated with enhanced
laque volume [20,21], as seen here with TRAIL deletion. The rea-
ons for this effect are unclear but raise the possibility of beneﬁcial
nﬂammatory reparation mechanisms within the vessel wall. This
s quite an attractive hypothesis for the data presented here in rela-
[
[s 215 (2011) 348–354 353
tion to TRAIL deletionwhen the enhanced atherosclerosis was only
seen with mild dietary stimuli, an effect overwhelmed by feeding
a fat enriched diet for a longer period.
5. Conclusion
The data presented here clearly show that TRAIL can atten-
uate atheromatous lesion formation. The underlying mechanism
appears to be that TRAIL promotes vascular cell apoptosis in
response to a mild dietary fat stimulus and that this effect is over-
come by extending the length of the fat-feeding period. Whilst the
role of TRAIL in vascular biology still remains controversial, these
data show thepotential for this cytokine system to limit the athero-
genic response to moderate atherogenic stimuli in the mouse.
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